Concepts (200)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 21 | 2024 | 1191 | 4.750 |
Why?
|
| Cardiomyopathies | 6 | 2023 | 552 | 2.100 |
Why?
|
| Biliary Atresia | 4 | 2024 | 201 | 1.780 |
Why?
|
| Acute-On-Chronic Liver Failure | 3 | 2024 | 62 | 1.600 |
Why?
|
| Liver Cirrhosis | 7 | 2024 | 1043 | 1.380 |
Why?
|
| Bile Acids and Salts | 5 | 2023 | 268 | 1.290 |
Why?
|
| Liver Failure, Acute | 4 | 2024 | 99 | 1.280 |
Why?
|
| Myocardium | 3 | 2021 | 1235 | 1.180 |
Why?
|
| End Stage Liver Disease | 5 | 2024 | 189 | 1.090 |
Why?
|
| Multiple Organ Failure | 3 | 2022 | 177 | 0.900 |
Why?
|
| Airway Extubation | 1 | 2024 | 74 | 0.880 |
Why?
|
| Renal Replacement Therapy | 3 | 2024 | 151 | 0.740 |
Why?
|
| Respiration, Artificial | 1 | 2023 | 583 | 0.700 |
Why?
|
| Liver | 4 | 2023 | 3083 | 0.700 |
Why?
|
| Myocardial Contraction | 2 | 2018 | 301 | 0.650 |
Why?
|
| Cholic Acids | 1 | 2018 | 32 | 0.630 |
Why?
|
| Tracheostomy | 1 | 2021 | 248 | 0.630 |
Why?
|
| Extracorporeal Circulation | 1 | 2018 | 55 | 0.610 |
Why?
|
| Critical Care | 2 | 2021 | 803 | 0.580 |
Why?
|
| Perioperative Care | 1 | 2021 | 447 | 0.580 |
Why?
|
| Plasma Exchange | 1 | 2018 | 104 | 0.570 |
Why?
|
| Cholic Acid | 3 | 2014 | 17 | 0.570 |
Why?
|
| Hemodynamics | 1 | 2021 | 951 | 0.570 |
Why?
|
| Cardiotonic Agents | 1 | 2018 | 156 | 0.570 |
Why?
|
| Receptors, G-Protein-Coupled | 2 | 2018 | 485 | 0.560 |
Why?
|
| Infant | 15 | 2024 | 13939 | 0.540 |
Why?
|
| Child | 23 | 2024 | 30496 | 0.460 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2014 | 87 | 0.440 |
Why?
|
| Hospital Costs | 2 | 2024 | 243 | 0.410 |
Why?
|
| Cholestasis | 2 | 2014 | 206 | 0.410 |
Why?
|
| Thrombolytic Therapy | 1 | 2014 | 248 | 0.400 |
Why?
|
| Fibrinolytic Agents | 1 | 2014 | 293 | 0.390 |
Why?
|
| Child, Preschool | 14 | 2024 | 16999 | 0.380 |
Why?
|
| Heart Atria | 1 | 2013 | 355 | 0.370 |
Why?
|
| Waiting Lists | 2 | 2021 | 267 | 0.370 |
Why?
|
| Postoperative Complications | 3 | 2024 | 5672 | 0.360 |
Why?
|
| Pulmonary Embolism | 1 | 2014 | 341 | 0.360 |
Why?
|
| Bile Duct Diseases | 1 | 2010 | 46 | 0.350 |
Why?
|
| Retrospective Studies | 16 | 2024 | 39751 | 0.350 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2010 | 169 | 0.320 |
Why?
|
| Anticoagulants | 4 | 2022 | 776 | 0.310 |
Why?
|
| Diet, Atherogenic | 1 | 2008 | 19 | 0.310 |
Why?
|
| Myocytes, Cardiac | 1 | 2013 | 703 | 0.300 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2011 | 400 | 0.300 |
Why?
|
| Citric Acid | 2 | 2018 | 53 | 0.300 |
Why?
|
| Pyridines | 2 | 2014 | 1311 | 0.290 |
Why?
|
| Hepatitis | 1 | 2008 | 92 | 0.290 |
Why?
|
| Blood Group Incompatibility | 2 | 2018 | 39 | 0.290 |
Why?
|
| Thrombosis | 3 | 2022 | 744 | 0.280 |
Why?
|
| ABO Blood-Group System | 2 | 2018 | 124 | 0.280 |
Why?
|
| Male | 25 | 2024 | 128105 | 0.270 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2008 | 210 | 0.270 |
Why?
|
| Atrial Fibrillation | 1 | 2013 | 730 | 0.260 |
Why?
|
| Mice, Knockout | 5 | 2023 | 5725 | 0.250 |
Why?
|
| Heart Failure | 1 | 2018 | 2336 | 0.250 |
Why?
|
| Liver Diseases | 2 | 2022 | 599 | 0.250 |
Why?
|
| Adolescent | 10 | 2024 | 32671 | 0.240 |
Why?
|
| Heart | 2 | 2011 | 1195 | 0.240 |
Why?
|
| Length of Stay | 3 | 2024 | 2002 | 0.240 |
Why?
|
| Mice, Inbred C57BL | 6 | 2023 | 7093 | 0.240 |
Why?
|
| Risk Factors | 6 | 2024 | 17849 | 0.230 |
Why?
|
| Critical Illness | 4 | 2021 | 739 | 0.220 |
Why?
|
| Humans | 29 | 2024 | 270457 | 0.220 |
Why?
|
| Ferritins | 2 | 2021 | 155 | 0.220 |
Why?
|
| Adenovirus Infections, Human | 1 | 2023 | 55 | 0.210 |
Why?
|
| Gastroenterology | 1 | 2024 | 195 | 0.200 |
Why?
|
| Hemodiafiltration | 1 | 2021 | 19 | 0.190 |
Why?
|
| Fatty Acids | 2 | 2016 | 442 | 0.180 |
Why?
|
| ADAMTS13 Protein | 1 | 2021 | 71 | 0.180 |
Why?
|
| Necrosis | 1 | 2022 | 594 | 0.180 |
Why?
|
| Female | 18 | 2024 | 148644 | 0.180 |
Why?
|
| Intensive Care Units | 2 | 2018 | 739 | 0.180 |
Why?
|
| Gastroenteritis | 1 | 2023 | 353 | 0.170 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 2 | 2021 | 183 | 0.170 |
Why?
|
| Bacterial Infections | 1 | 2023 | 509 | 0.170 |
Why?
|
| Treatment Outcome | 8 | 2022 | 33708 | 0.160 |
Why?
|
| Prognosis | 4 | 2024 | 22475 | 0.160 |
Why?
|
| Ventricular Function, Left | 2 | 2014 | 564 | 0.160 |
Why?
|
| von Willebrand Factor | 1 | 2021 | 245 | 0.160 |
Why?
|
| Serum Albumin, Human | 1 | 2018 | 14 | 0.160 |
Why?
|
| Hemofiltration | 1 | 2018 | 21 | 0.160 |
Why?
|
| Cytoprotection | 1 | 2018 | 64 | 0.160 |
Why?
|
| Venous Thrombosis | 1 | 2022 | 381 | 0.160 |
Why?
|
| Biliary Tract Diseases | 1 | 2018 | 65 | 0.150 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2018 | 99 | 0.150 |
Why?
|
| Cause of Death | 2 | 2018 | 779 | 0.150 |
Why?
|
| Sepsis | 1 | 2023 | 687 | 0.150 |
Why?
|
| Exercise Tolerance | 1 | 2018 | 106 | 0.150 |
Why?
|
| Bacteremia | 1 | 2023 | 722 | 0.150 |
Why?
|
| Liver Failure | 1 | 2018 | 141 | 0.140 |
Why?
|
| Preoperative Period | 1 | 2018 | 347 | 0.140 |
Why?
|
| Disease Models, Animal | 3 | 2018 | 7371 | 0.140 |
Why?
|
| Animals | 9 | 2023 | 62021 | 0.140 |
Why?
|
| Adaptation, Physiological | 1 | 2018 | 346 | 0.140 |
Why?
|
| Infant, Newborn | 4 | 2024 | 8626 | 0.130 |
Why?
|
| Echocardiography | 2 | 2019 | 1231 | 0.120 |
Why?
|
| Retinoid X Receptor alpha | 1 | 2013 | 39 | 0.110 |
Why?
|
| Acute Kidney Injury | 1 | 2021 | 758 | 0.110 |
Why?
|
| Follow-Up Studies | 3 | 2024 | 15191 | 0.110 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2014 | 139 | 0.110 |
Why?
|
| Tissue Donors | 1 | 2018 | 812 | 0.110 |
Why?
|
| Signal Transduction | 4 | 2018 | 12104 | 0.110 |
Why?
|
| Survival Rate | 2 | 2024 | 12513 | 0.100 |
Why?
|
| Drug Resistance | 1 | 2014 | 609 | 0.100 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2014 | 317 | 0.100 |
Why?
|
| Cardiovirus Infections | 1 | 2011 | 8 | 0.100 |
Why?
|
| Catheterization | 1 | 2014 | 417 | 0.100 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2011 | 97 | 0.090 |
Why?
|
| Mice | 6 | 2023 | 35592 | 0.090 |
Why?
|
| Time Factors | 3 | 2017 | 12991 | 0.090 |
Why?
|
| Dicarbethoxydihydrocollidine | 1 | 2010 | 4 | 0.090 |
Why?
|
| Ventricular Remodeling | 1 | 2011 | 188 | 0.090 |
Why?
|
| Glycogen | 1 | 2010 | 82 | 0.090 |
Why?
|
| Recovery of Function | 1 | 2014 | 684 | 0.090 |
Why?
|
| Cells, Cultured | 1 | 2018 | 5690 | 0.090 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 2010 | 102 | 0.090 |
Why?
|
| Survival Analysis | 1 | 2021 | 9294 | 0.090 |
Why?
|
| Myocarditis | 1 | 2011 | 181 | 0.080 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 9041 | 0.080 |
Why?
|
| Radiography | 1 | 2014 | 1988 | 0.080 |
Why?
|
| Portal Vein | 2 | 2022 | 363 | 0.080 |
Why?
|
| Amino Acids | 2 | 2023 | 784 | 0.080 |
Why?
|
| Respiratory Function Tests | 1 | 2010 | 355 | 0.080 |
Why?
|
| Oxygen Consumption | 1 | 2010 | 417 | 0.080 |
Why?
|
| Cholesterol, Dietary | 1 | 2008 | 52 | 0.080 |
Why?
|
| Chemokine CXCL2 | 1 | 2008 | 33 | 0.080 |
Why?
|
| Chemokine CCL5 | 1 | 2008 | 76 | 0.080 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2008 | 95 | 0.070 |
Why?
|
| Chemokine CCL2 | 1 | 2008 | 198 | 0.070 |
Why?
|
| Fibrosis | 1 | 2010 | 732 | 0.070 |
Why?
|
| Case-Control Studies | 2 | 2018 | 6204 | 0.070 |
Why?
|
| Heart Ventricles | 1 | 2011 | 846 | 0.070 |
Why?
|
| Dietary Fats | 1 | 2008 | 341 | 0.070 |
Why?
|
| Cohort Studies | 1 | 2019 | 9466 | 0.070 |
Why?
|
| Fatty Liver | 1 | 2008 | 247 | 0.070 |
Why?
|
| Gene Expression | 2 | 2013 | 3638 | 0.070 |
Why?
|
| Recurrence | 1 | 2014 | 4877 | 0.060 |
Why?
|
| Ultrasonography | 1 | 2011 | 1933 | 0.060 |
Why?
|
| Brain Edema | 1 | 2024 | 96 | 0.060 |
Why?
|
| Receptors, Purinergic | 1 | 2023 | 17 | 0.060 |
Why?
|
| Receptors, Purinergic P2Y2 | 1 | 2023 | 18 | 0.060 |
Why?
|
| India | 1 | 2024 | 313 | 0.060 |
Why?
|
| Fatigue | 1 | 2010 | 1278 | 0.060 |
Why?
|
| Nucleotides | 1 | 2023 | 174 | 0.050 |
Why?
|
| Biomarkers | 1 | 2014 | 5054 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2024 | 4364 | 0.050 |
Why?
|
| GTP-Binding Proteins | 1 | 2023 | 342 | 0.050 |
Why?
|
| Catheters | 1 | 2022 | 133 | 0.050 |
Why?
|
| Lipopolysaccharides | 1 | 2023 | 588 | 0.050 |
Why?
|
| Hepatic Artery | 1 | 2022 | 256 | 0.050 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2021 | 166 | 0.040 |
Why?
|
| Thrombectomy | 1 | 2021 | 169 | 0.040 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2021 | 162 | 0.040 |
Why?
|
| Texas | 1 | 2011 | 6432 | 0.040 |
Why?
|
| Arginine | 1 | 2023 | 508 | 0.040 |
Why?
|
| Oxidoreductases | 1 | 2021 | 168 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 4323 | 0.040 |
Why?
|
| Cytokines | 2 | 2023 | 2824 | 0.040 |
Why?
|
| Consensus | 1 | 2024 | 1102 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2011 | 6776 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2024 | 699 | 0.040 |
Why?
|
| Phenotype | 1 | 2010 | 6497 | 0.040 |
Why?
|
| Graft Survival | 1 | 2022 | 1079 | 0.040 |
Why?
|
| Gene Deletion | 1 | 2023 | 1475 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2024 | 1320 | 0.040 |
Why?
|
| RNA, Messenger | 1 | 2008 | 6394 | 0.040 |
Why?
|
| Proportional Hazards Models | 2 | 2017 | 5104 | 0.040 |
Why?
|
| Adenoviridae | 1 | 2023 | 1497 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2017 | 6256 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2018 | 481 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2021 | 13383 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2021 | 3028 | 0.030 |
Why?
|
| Linear Models | 1 | 2018 | 1095 | 0.030 |
Why?
|
| Renal Dialysis | 1 | 2021 | 920 | 0.030 |
Why?
|
| Graft Rejection | 1 | 2018 | 845 | 0.030 |
Why?
|
| Mice, Inbred DBA | 1 | 2013 | 117 | 0.030 |
Why?
|
| United States | 2 | 2024 | 15856 | 0.030 |
Why?
|
| Mice, 129 Strain | 1 | 2013 | 160 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 2327 | 0.030 |
Why?
|
| Mutant Proteins | 1 | 2013 | 234 | 0.030 |
Why?
|
| Mice, Mutant Strains | 1 | 2013 | 655 | 0.030 |
Why?
|
| Encephalomyocarditis virus | 1 | 2011 | 8 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2018 | 1430 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2017 | 1233 | 0.020 |
Why?
|
| Hepatocytes | 1 | 2013 | 336 | 0.020 |
Why?
|
| Calcium | 1 | 2017 | 1593 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2013 | 1472 | 0.020 |
Why?
|
| Viral Load | 1 | 2011 | 484 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 1516 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2013 | 1309 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 1200 | 0.020 |
Why?
|
| Disease Progression | 1 | 2018 | 6842 | 0.020 |
Why?
|
| Age Factors | 1 | 2016 | 5462 | 0.020 |
Why?
|
| Adult | 2 | 2024 | 81754 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2011 | 3592 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 3607 | 0.020 |
Why?
|
| Young Adult | 1 | 2024 | 22152 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2011 | 4222 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 7646 | 0.010 |
Why?
|
| Apoptosis | 1 | 2013 | 7753 | 0.010 |
Why?
|